COVID-19
The pharmaceutical industry continues to demonstrate its willingness to team up in the ongoing combat against the global COVID-19 pandemic.
The Phase III analysis of its COVID-19 vaccine candidate shows the medication demonstrated 89.3% efficacy in a large-scale study conducted in the U.K. that included the most common strain of the virus, as well as variants.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Senior White House adviser Andy Slavitt said the administration is striving to meet its goal of ensuring enough vaccine supply by summer, but acknowledged there could be some hurdles that will prevent that timeline.
The data is continuing to come in on the various COVID-19 variants, and so far the news is pretty good.
J&J indicated it will soon release Phase III data and could file for Emergency Use Authorization with the U.S. Food and Drug Administration by the end of the month.
Police have sealed off the area, according to the report. Few details were available, but eye witnesses said a robot was investigating a suspicious package found at the plant.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
PRESS RELEASES